Kezar Life Sciences Inc. is a US-based pharmaceutical company with a medium risk ESG score of 25.3. Specializing in clinical-stage biotechnology, Kezar focuses on developing small molecule therapeutics for autoimmunity and cancer treatment. Key product candidates include Zetomipzomib (KZR-616) and KZR-261.